What is claimed is:

1. A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-tachycardia pacing energy to the heart, the power supply comprising:

a capacitor subsystem for storing the anti-tachycardia pacing energy for delivery to the patient's heart; and

a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-tachycardia pacing energy to the capacitor subsystem.

2. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

3. The power supply of claim 2, wherein the anti-tachycardia pacing energy comprises a biphasic

waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

4. The power supply of claim 2, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

5. The power supply of claim 2, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

6. The power supply of claim 2, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

7. The power supply of claim 2, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

8. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

9. The power supply of claim 8, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

10. The power supply of claim 8, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

11. The power supply of claim 8, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

12. The power supply of claim 8, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

13. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a biphasic waveform further comprising a portion that is positive in polarity and a portion that is negative in polarity.

14. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a biphasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

15. The power supply of claim 14, wherein the biphasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

16. The power supply of claim 15, wherein the biphasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

17. The power supply of claim 1, wherein the lead system comprises an electrode located proximate

the sternum and anterior portion of the patient's heart.

18. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises burst pacing.

19. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises ramp pacing.

20. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

21. The power supply of claim 20, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

22. The power supply of claim 20, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

23. The power supply of claim 20, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

24. The power supply of claim 20, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

25. The power supply of claim 20, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

26. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

27. The power supply of claim 26, wherein the anti-tachycardia pacing energy comprises a monophasic

waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

28. The power supply of claim 26, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

29. The power supply of claim 26, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

30. The power supply of claim 26, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

31. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

32. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

33. The power supply of claim 32, wherein the monophasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

34. The power supply of claim 33, wherein the monophasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

35. The power supply of claim 1, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

36. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises burst pacing.

37. The power supply of claim 1, wherein the anti-tachycardia pacing energy comprises ramp pacing.

38. Current output system for an implantable cardioverter-defibrillator using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-tachycardia pacing energy to the heart, the power supply comprising:

an energy storage system for storing the anti-tachycardia pacing energy for delivery to the patient's heart; and

an energy source system electrically coupled to the capacitor subsystem for providing the anti-tachycardia pacing energy to the capacitor subsystem.

39. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

40. Current output system of claim 39, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

41. Current output system of claim 39, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

42. Current output system of claim 39, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

43. Current output system of claim 39, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

44. Current output system of claim 39, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

45. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

46. Current output system of claim 45, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

47. Current output system of claim 45, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

48. Current output system of claim 45, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

49. Current output system of claim 45, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

50. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a biphasic waveform further comprising a portion that is positive in polarity and a portion that is negative in polarity.

51. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a biphasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

52. Current output system of claim 51, wherein the biphasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

53. The current output system of claim 52, wherein the biphasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

54. The current output system of claim 38, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

55. The current output system of claim 38, wherein the anti-tachycardia pacing energy comprises burst pacing.

56. The current output system of claim 38, wherein the anti-tachycardia pacing energy comprises ramp pacing.

57. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

58. Current output system of claim 57, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

59. Current output system of claim 57, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

60. Current output system of claim 57, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

61. Current output system of claim 57, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

62. Current output system of claim 57, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

63. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

64. Current output system of claim 63, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

65. Current output system of claim 63, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

66. Current output system of claim 63, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

67. Current output system of claim 63, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

68. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a monophasic waveform further comprising a positive voltage portion.

69. Current output system of claim 38, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

70. Current output system of claim 69, wherein the monophasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

71. The current output system of claim 70, wherein the monophasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

72. The current output system of claim 38, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

73. The current output system of claim 38, wherein the anti-tachycardia pacing energy comprises burst pacing.

74. The current output system of claim 38, wherein the anti-tachycardia pacing energy comprises ramp pacing.

75. An implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib within a patient, the implantable cardioverter-defibrillator comprising:

a housing having an electrically conductive surface on an outer surface of the housing;

a lead assembly electrically coupled to the housing and having an electrode, wherein the lead assembly does not directly contact the patient's heart or reside in the intrathorasic blood vessels;

a capacitor subsystem located within the housing and electrically coupled to the electrically conductive surface and the electrode for storing anti-tachycardia pacing energy and for delivering the anti-tachycardia pacing energy to the patient's heart

through the electrically conductive surface and the electrode; and

a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-tachycardia pacing energy to the capacitor subsystem.

76. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

77. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

78. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

79. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

80. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

81. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

82. The implantable cardioverter-defibrillator of claim 76, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

83. The implantable cardioverter-defibrillator of claim 82, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

84. The implantable cardioverter-defibrillator of claim 82, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

85. The implantable cardioverter-defibrillator of claim 82, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

86. The implantable cardioverter-defibrillator of claim 82, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

87. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a biphasic waveform further comprising a portion that is positive in polarity and a portion that is negative in polarity.

88. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a biphasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

89. The implantable cardioverter-defibrillator of claim 88, wherein the biphasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

90. The implantable cardioverter-defibrillator of claim 89, wherein the monophasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

91. The implantable cardioverter-defibrillator of claim 75, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

92. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises burst pacing.

93. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises ramp pacing.

94. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

95. The implantable cardioverter-defibrillator of claim 94, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak

current that is approximately one milliamp to approximately 50 milliamps.

96. The implantable cardioverter-defibrillator of claim 94, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

97. The implantable cardioverter-defibrillator of claim 94, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

98. The implantable cardioverter-defibrillator of claim 94, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

99. The implantable cardioverter-defibrillator of claim 94, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak

current that is approximately 200 milliamps to approximately 250 milliamps.

100. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

101. The implantable cardioverter-defibrillator of claim 100, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

102. The implantable cardioverter-defibrillator of claim 100, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

103. The implantable cardioverter-defibrillator of claim 100, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse

width that is approximately 20 milliseconds to approximately 30 milliseconds.

104. The implantable cardioverter-defibrillator of claim 100, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

105. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

106. The implantable cardioverter-defibrillator of claim 105, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

107. The implantable cardioverter-defibrillator of claim 106, wherein the monophasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

108. The implantable cardioverter-defibrillator of claim 107, wherein the monophasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

109. The implantable cardioverter-defibrillator of claim 75, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

110. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises burst pacing.

111. The implantable cardioverter-defibrillator of claim 75, wherein the anti-tachycardia pacing energy comprises ramp pacing.

112. A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-tachycardia pacing energy to the heart, the method comprising:

generating anti-tachycardia pacing energy;

storing the anti-tachycardia pacing energy; and

delivering the anti-tachycardia pacing energy to the patient's heart.

113. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

114. The method of claim 113, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

115. The method of claim 113, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

116. The method of claim 113, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

117. The method of claim 113, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

118. The method of claim 113, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

119. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

120. The method of claim 119, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

121. The method of claim 119, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

122. The method of claim 119, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

123. The method of claim 119, wherein the anti-tachycardia pacing energy comprises a biphasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

124. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a biphasic waveform further comprising a portion that is

positive in polarity and a portion that is negative in polarity.

125. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a biphasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

126. The method of claim 125, wherein the biphasic waveform is provided after a patient's heart rate is equal to or greater than approximately 100 beats/minute.

127. The method of claim 126, wherein the biphasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

128. The method of claim 112, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

129. The method of claim 112, wherein the anti-tachycardia pacing energy comprises burst pacing.

130. The method of claim 112, wherein the anti-tachycardia pacing energy comprises ramp pacing.

131. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 250 milliamps.

132. The method of claim 131, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately one milliamp to approximately 50 milliamps.

133. The method of claim 131, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 50 milliamps to approximately 100 milliamps.

134. The method of claim 131, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 100 milliamps to approximately 150 milliamps.

135. The method of claim 131, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 150 milliamps to approximately 200 milliamps.

136. The method of claim 131, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a peak current that is approximately 200 milliamps to approximately 250 milliamps.

137. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

138. The method of claim 137, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

139. The method of claim 137, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

140. The method of claim 137, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

141. The method of claim 137, wherein the anti-tachycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

142. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

143. The method of claim 112, wherein the anti-tachycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 100 to approximately 350 stimuli/minute.

144. The method of claim 143, wherein the monophasic waveform is provided after a patient's

heart rate is equal or less than approximately 100 beats/minute.

145. The method of claim 144, wherein the monophasic waveform is provided after a patient's heart rate is associated with a monomorphic ECG pattern.

146. The method of claim 112, wherein the lead system comprises an electrode located proximate the sternum and anterior portion of the patient's heart.

147. The method of claim 112, wherein the anti-tachycardia pacing energy comprises burst pacing.

148. The method of claim 112, wherein the anti-tachycardia pacing energy comprises ramp pacing.

149. The power supply of claim 1, wherein the battery subsystem and the capacitor system provide a sufficient voltage to provide an anti-tachycardia pacing energy comprising an approximately constant current.